Part 2：B-cell Malignancies
1 clinical trials · Condition
◉ Watch Part 2：B-cell Malignancies
| Record | Firm | Date |
|---|---|---|
| A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies (NCT04014205) | Beijing InnoCare Pharma Tech Co., Ltd. | 2019-11-18 |
Track Part 2：B-cell Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.